The FDA has cleared AD-NP1, a drug developed by University of California, Los Angeles (UCLA) for heart tissue regeneration, to enter clinical trials. The monoclonal antibody blocks the production of ENPP1 protein, which was found to interfere with healing after a heart attack.
Astrazeneca AB has patented new proprotein convertase subtilisin/kexin-type 9 (PCSK9) inhibitors reported to be useful for the treatment of cardiovascular disorders.
Hypertension is a frequent chronic condition commonly affecting the elderly, but its incidence is increasing among younger individuals. The estimates predict that 1.28 billion individuals aged 30-79 are currently living with hypertension worldwide. Despite the availability of effective treatments, monotherapy often leads to resistance and the management of adverse effects remains cumbersome.
At the recent European Respiratory Society meeting, researchers from 35Pharma Inc. presented data on HS-235, an activin receptor inhibitor designed to neutralize activins and growth differentiation factors (GDFs). Disorders such as heart failure (HF) and pulmonary hypertension (PH) are associated with dysregulated activin and GDFs without neutralizing bone morphogenetic proteins such as BMP-9 and BMP-10, which play key roles in lymphatic and vascular homeostasis.
The University of California has synthesized proprotein convertase subtilisin/kexin-type 9 (PCSK9) inhibitors reported to be useful for the treatment of cancer, atherosclerosis and stroke.
Many patients who survive myocardial infarction go on to experience heart failure. Researchers at Qilu Hospital of Shandong University found that bone morphogenetic protein 1 (BMP1) was upregulated in patients after myocardial infarction, as well as in a mouse model of the same condition.
CSPC Pharmaceutical Group Ltd. has obtained clearance from China’s National Medical Products Administration (NMPA) to conduct clinical trials in China with SYH-2070 injection, a double-stranded small interfering RNA (siRNA) drug for the treatment of hypertriglyceridemia or mixed hyperlipidemia.
Scientists at Unity Health Toronto and University of British Columbia have identified aeroplysinin derivatives reported to be useful for the treatment of asthma, atherosclerosis, autoimmune disease, diabetic nephropathy and more.
In heart failure, the heart does not oxygenate body tissues adequately. A standard treatment is SGLT2 inhibitors such as empagliflozin and dapagliflozin, derived from the national product phlorizin. However, long-term use of these inhibitors increases risk of renal damage and euglycemic diabetic ketoacidosis.
RSS
